

Senate
File
513
-
Reprinted


SENATE
FILE
513


BY
COMMITTEE
ON
HUMAN


RESOURCES


(SUCCESSOR
TO
SF
348)


(As
Amended
and
Passed
by
the
Senate
March
27,
2019
)


A
BILL
FOR


An
Act
relating
to
the
prescribing
and
dispensing
of
1


self-administered
hormonal
contraceptives.
2


BE
IT
ENACTED
BY
THE
GENERAL
ASSEMBLY
OF
THE
STATE
OF
IOWA:
3


SF
513
(4)
88


pf/rh/mb



S.F.
513


Section
1.
Section
155A.3,
Code
2019,
is
amended
by
adding
1


the
following
new
subsections:
2


NEW
SUBSECTION


.
10A.
“Department”
means
the
department
of
3


public
health.
4


NEW
SUBSECTION


.
44A.
“Self-administered
hormonal
5


contraceptive”
means
a
self-administered
hormonal
contraceptive
6


that
is
approved
by
the
United
States
food
and
drug
7


administration
to
prevent
pregnancy.
“Self-administered
8


hormonal
contraceptive”
includes
an
oral
hormonal
contraceptive,
9


a
hormonal
vaginal
ring,
and
a
hormonal
contraceptive
patch,
10


but
does
not
include
any
drug
intended
to
induce
an
abortion
as
11


defined
in
section
146.1.
12


NEW
SUBSECTION


.
44B.
“Standing
order”
means
a
preauthorized
13


medication
order
with
specific
instructions
from
the
medical
14


director
of
the
department
to
dispense
a
medication
under
15


clearly
defined
circumstances.
16


Sec.
2.
NEW
SECTION


.
155A.47
Pharmacist
dispensing
of
17


self-administered
hormonal
contraceptives
——
standing
order
——
18


requirements
——
limitations
of
liability.
19


1.
a.
Notwithstanding
any
provision
of
law
to
the
contrary,
20


a
pharmacist
may
dispense
a
self-administered
hormonal
21


contraceptive
to
a
patient,
who
is
at
least
eighteen
years
of
22


age,
pursuant
to
a
standing
order
established
by
the
medical
23


director
of
the
department
in
accordance
with
this
section.
24


b.
In
dispensing
a
self-administered
hormonal
contraceptive
25


to
a
patient
under
this
section,
a
pharmacist
shall
comply
with
26


the
following:
27


(1)
For
an
initial
dispensing
of
a
self-administered
28


hormonal
contraceptive,
the
pharmacist
may
dispense
only
up
29


to
a
three-month
supply
at
one
time
of
the
self-administered
30


hormonal
contraceptive.
31


(2)
For
any
subsequent
dispensing
of
the
same
32


self-administered
hormonal
contraceptive,
the
pharmacist
33


may
dispense
up
to
a
twelve-month
supply
at
one
time
of
the
34


self-administered
hormonal
contraceptive.
35


-1-


SF
513
(4)
88


pf/rh/mb


1/
8







S.F.
513


2.
A
pharmacist
who
dispenses
a
self-administered
hormonal
1


contraceptive
in
accordance
with
this
section
shall
not
2


require
any
other
prescription
drug
order
authorized
by
a
3


practitioner
prior
to
dispensing
the
self-administered
hormonal
4


contraceptive
to
a
patient.
5


3.
The
medical
director
of
the
department
may
establish
a
6


standing
order
authorizing
the
dispensing
of
self-administered
7


hormonal
contraceptives
by
a
pharmacist
who
does
all
of
the
8


following:
9


a.
Complies
with
the
standing
order
established
pursuant
to
10


this
section.
11


b.
Retains
a
record
of
each
patient
to
whom
a
12


self-administered
hormonal
contraceptive
is
dispensed
under
13


this
section
and
submits
the
record
to
the
department.
14


4.
The
standing
order
shall
require
a
pharmacist
who
15


dispenses
self-administered
hormonal
contraceptives
under
this
16


section
to
do
all
of
the
following:
17


a.
Complete
a
standardized
training
program
and
continuing
18


education
requirements
approved
by
the
board
in
consultation
19


with
the
department
that
are
related
to
prescribing
20


self-administered
hormonal
contraceptives
and
include
education
21


regarding
all
contraceptive
methods
approved
by
the
United
22


States
food
and
drug
administration.
23


b.
Obtain
a
completed
self-screening
risk
assessment,
24


approved
by
the
department
in
collaboration
with
the
board
and
25


the
board
of
medicine,
from
each
patient,
verify
the
identity
26


and
age
of
each
patient,
and
perform
a
blood
pressure
screening
27


on
each
patient,
prior
to
dispensing
the
self-administered
28


hormonal
contraceptive
to
the
patient.
29


c.
Provide
the
patient
with
all
of
the
following:
30


(1)
Written
information
regarding
all
of
the
following:
31


(a)
The
importance
of
completing
an
appointment
with
the
32


patient’s
primary
care
or
women’s
health
care
practitioner
33


to
obtain
preventative
care,
including
but
not
limited
to
34


recommended
tests
and
screenings.
35


-2-


SF
513
(4)
88


pf/rh/mb


2/
8



S.F.
513


(b)
The
effectiveness
and
availability
of
long-acting
1


reversible
contraceptives
as
an
alternative
to
2


self-administered
hormonal
contraceptives.
3


(2)
A
copy
of
the
record
of
the
pharmacist’s
encounter
with
4


the
patient
that
includes
all
of
the
following:
5


(a)
The
patient’s
completed
self-screening
risk
assessment.
6


(b)
A
description
of
the
contraceptive
dispensed,
or
the
7


basis
for
not
dispensing
a
contraceptive.
8


(3)
Patient
counseling
regarding
all
of
the
following:
9


(a)
The
appropriate
administration
and
storage
of
the
10


self-administered
hormonal
contraceptive.
11


(b)
Potential
side
effects
and
risks
of
the
12


self-administered
hormonal
contraceptive.
13


(c)
The
need
for
backup
contraception.
14


(d)
When
to
seek
emergency
medical
attention.
15


(e)
The
risk
of
contracting
a
sexually
transmitted
16


infection
or
disease,
and
ways
to
reduce
such
a
risk.
17


5.
The
standing
order
established
pursuant
to
this
section
18


shall
prohibit
a
pharmacist
who
dispenses
a
self-administered
19


hormonal
contraceptive
under
this
section
from
doing
any
of
the
20


following:
21


a.
Requiring
a
patient
to
schedule
an
appointment
with
22


the
pharmacist
for
the
prescribing
or
dispensing
of
a
23


self-administered
hormonal
contraceptive.
24


b.
Dispensing
self-administered
hormonal
contraceptives
to
25


a
patient
for
more
than
twenty-four
months
after
the
date
a
26


self-administered
hormonal
contraceptive
is
initially
dispensed
27


to
the
patient
without
the
patient’s
attestation
that
the
28


patient
has
consulted
with
a
primary
care
or
women’s
health
29


care
practitioner
during
the
preceding
twenty-four
months.
30


c.
Dispensing
a
self-administered
hormonal
contraceptive
to
31


a
patient
if
the
results
of
the
self-screening
risk
assessment
32


completed
by
a
patient
pursuant
to
subsection
4,
paragraph
33


“b”
,
indicate
it
is
unsafe
for
the
pharmacist
to
dispense
the
34


self-administered
hormonal
contraceptive
to
the
patient,
in
35


-3-


SF
513
(4)
88


pf/rh/mb


3/
8



S.F.
513


which
case
the
pharmacist
shall
refer
the
patient
to
a
primary
1


care
or
women’s
health
care
practitioner.
2


6.
A
pharmacist
who
dispenses
a
self-administered
hormonal
3


contraceptive
and
the
medical
director
of
the
department
who
4


establishes
a
standing
order
in
compliance
with
this
section
5


shall
be
immune
from
criminal
and
civil
liability
arising
from
6


any
damages
caused
by
the
dispensing,
administering,
or
use
of
7


a
self-administered
hormonal
contraceptive
or
the
establishment
8


of
the
standing
order,
provided
that
the
pharmacist
acts
9


reasonably
and
in
good
faith.
The
medical
director
of
the
10


department
shall
be
considered
to
be
acting
within
the
scope
11


of
the
medical
director’s
office
and
employment
for
purposes
12


of
chapter
669
in
the
establishment
of
a
standing
order
in
13


compliance
with
this
section.
14


7.
The
department,
in
collaboration
with
the
board
and
15


the
board
of
medicine,
and
in
consideration
of
the
guidelines
16


established
by
the
American
congress
of
obstetricians
and
17


gynecologists,
shall
adopt
rules
pursuant
to
chapter
17A
to
18


administer
this
chapter.
19


Sec.
3.
Section
514C.19,
Code
2019,
is
amended
to
read
as
20


follows:
21


514C.19
Prescription
contraceptive
coverage.
22


1.
Notwithstanding
the
uniformity
of
treatment
requirements
23


of
section
514C.6
,
a
group
policy
,


or
contract
,
or
plan
24


providing
for
third-party
payment
or
prepayment
of
health
or
25


medical
expenses
shall
not
do
either
of
the
following
comply
26


as
follows
:


27


a.
Exclude


Such
policy,
contract,
or
plan
shall
not
28


exclude
or
restrict
benefits
for
prescription
contraceptive
29


drugs
or
prescription
contraceptive
devices
which
prevent
30


conception
and
which
are
approved
by
the
United
States
31


food
and
drug
administration,
or
generic
equivalents
32


approved
as
substitutable
by
the
United
States
food
and
drug
33


administration,
if
such
policy
,


or
contract
,
or
plan
provides
34


benefits
for
other
outpatient
prescription
drugs
or
devices.
35


-4-


SF
513
(4)
88


pf/rh/mb


4/
8















S.F.
513


However,
such
policy,
contract,
or
plan
shall
specifically
1


provide
for
payment,
including
reimbursement
for
pharmacist


2


consultations,
for
a
self-administered
hormonal
contraceptive,
3


as
prescribed
by
a
practitioner
as
defined
in
section
4


155A.3,
or
as
prescribed
by
standing
order
and
dispensed
by
a


5


pharmacist
pursuant
to
section
155A.47,
including
payment
for


6


up
to
an
initial
three-month
supply
of
the
self-administered
7


hormonal
contraceptive
dispensed
at
one
time
and
for
up
to
a
8


twelve-month
supply
of
the
same
self-administered
hormonal


9


contraceptive
subsequently
dispensed
at
one
time.
10


b.
Exclude


Such
policy,
contract,
or
plan
shall
not
exclude
11


or
restrict
benefits
for
outpatient
contraceptive
services
12


which
are
provided
for
the
purpose
of
preventing
conception
if
13


such
policy
,


or
contract
,
or
plan
provides
benefits
for
other
14


outpatient
services
provided
by
a
health
care
professional.
15


2.
A
person
who
provides
a
group
policy
,
or
contract
,
or
16


plan
providing
for
third-party
payment
or
prepayment
of
health
17


or
medical
expenses
which
is
subject
to
subsection
1
shall
not
18


do
any
of
the
following:
19


a.
Deny
to
an
individual
eligibility,
or
continued
20


eligibility,
to
enroll
in
or
to
renew
coverage
under
the
terms
21


of
the
policy
,


or
contract
,
or
plan
because
of
the
individual’s
22


use
or
potential
use
of
such
prescription
contraceptive
drugs
23


or
devices,
or
use
or
potential
use
of
outpatient
contraceptive
24


services.
25


b.
Provide
a
monetary
payment
or
rebate
to
a
covered
26


individual
to
encourage
such
individual
to
accept
less
than
the
27


minimum
benefits
provided
for
under
subsection
1
.
28


c.
Penalize
or
otherwise
reduce
or
limit
the
reimbursement
29


of
a
health
care
professional
because
such
professional
30


prescribes
contraceptive
drugs
or
devices,
or
provides
31


contraceptive
services.
32


d.
Provide
incentives,
monetary
or
otherwise,
to
a
health
33


care
professional
to
induce
such
professional
to
withhold
34


from
a
covered
individual
contraceptive
drugs
or
devices,
or
35


-5-


SF
513
(4)
88


pf/rh/mb


5/
8

























S.F.
513


contraceptive
services.
1


3.
This
section
shall
not
be
construed
to
prevent
a
2


third-party
payor
from
including
deductibles,
coinsurance,
or
3


copayments
under
the
policy
,


or
contract,
or
plan
as
follows:
4


a.
A
deductible,
coinsurance,
or
copayment
for
benefits
5


for
prescription
contraceptive
drugs
shall
not
be
greater
than
6


such
deductible,
coinsurance,
or
copayment
for
any
outpatient
7


prescription
drug
for
which
coverage
under
the
policy
,
or
8


contract
,
or
plan


is
provided.
9


b.
A
deductible,
coinsurance,
or
copayment
for
benefits
for
10


prescription
contraceptive
devices
shall
not
be
greater
than
11


such
deductible,
coinsurance,
or
copayment
for
any
outpatient
12


prescription
device
for
which
coverage
under
the
policy
,


or
13


contract
,
or
plan


is
provided.
14


c.
A
deductible,
coinsurance,
or
copayment
for
benefits
for
15


outpatient
contraceptive
services
shall
not
be
greater
than
16


such
deductible,
coinsurance,
or
copayment
for
any
outpatient
17


health
care
services
for
which
coverage
under
the
policy
,


or
18


contract
,
or
plan


is
provided.
19


4.
This
section
shall
not
be
construed
to
require
a
20


third-party
payor
under
a
policy
,


or
contract
,
or
plan
21


to
provide
benefits
for
experimental
or
investigational
22


contraceptive
drugs
or
devices,
or
experimental
or
23


investigational
contraceptive
services,
except
to
the
extent
24


that
such
policy
,


or
contract
,
or
plan
provides
coverage
for
25


other
experimental
or
investigational
outpatient
prescription
26


drugs
or
devices,
or
experimental
or
investigational
outpatient
27


health
care
services.


28


5.
This
section
shall
not
be
construed
to
limit
or
otherwise


29


discourage
the
use
of
generic
equivalent
drugs
approved
by
the
30


United
States
food
and
drug
administration,
whenever
available
31


and
appropriate.
This
section
,
when
a
brand
name
drug
is
32


requested
by
a
covered
individual
and
a
suitable
generic
33


equivalent
is
available
and
appropriate,
shall
not
be
construed
34


to
prohibit
a
third-party
payor
from
requiring
the
covered
35


-6-


SF
513
(4)
88


pf/rh/mb


6/
8





















S.F.
513


individual
to
pay
a
deductible,
coinsurance,
or
copayment
1


consistent
with
subsection
3
,
in
addition
to
the
difference
of
2


the
cost
of
the
brand
name
drug
less
the
maximum
covered
amount
3


for
a
generic
equivalent.
4


6.
A
person
who
provides
an
individual
policy
,
or
contract
,
5


or
plan


providing
for
third-party
payment
or
prepayment
of
6


health
or
medical
expenses
shall
make
available
a
coverage
7


provision
that
satisfies
the
requirements
in
subsections
8


1
through
5
in
the
same
manner
as
such
requirements
are
9


applicable
to
a
group
policy
,


or
contract
,
or
plan
under
those
10


subsections.
The
policy
,


or
contract
,
or
plan
shall
provide
11


that
the
individual
policyholder
may
reject
the
coverage
12


provision
at
the
option
of
the
policyholder.
13


7.
a.
This
section
applies
to
the
following
classes
of
14


third-party
payment
provider
contracts
,


or
policies
,
or
plan
15


delivered,
issued
for
delivery,
continued,
or
renewed
in
this
16


state
on
or
after
July
1,
2000
January
1,
2020
:
17


(1)
Individual
or
group
accident
and
sickness
insurance
18


providing
coverage
on
an
expense-incurred
basis.
19


(2)
An
individual
or
group
hospital
or
medical
service
20


contract
issued
pursuant
to
chapter
509
,
514
,
or
514A
.
21


(3)
An
individual
or
group
health
maintenance
organization
22


contract
regulated
under
chapter
514B
.
23


(4)
Any
other
entity
engaged
in
the
business
of
insurance,
24


risk
transfer,
or
risk
retention,
which
is
subject
to
the
25


jurisdiction
of
the
commissioner.
26


(5)
A
plan
established
pursuant
to
chapter
509A
for
public
27


employees.
28


b.
This
section
shall
not
apply
to
accident-only,
29


specified
disease,
short-term
hospital
or
medical,
hospital
30


confinement
indemnity,
credit,
dental,
vision,
Medicare
31


supplement,
long-term
care,
basic
hospital
and
medical-surgical
32


expense
coverage
as
defined
by
the
commissioner,
disability
33


income
insurance
coverage,
coverage
issued
as
a
supplement
34


to
liability
insurance,
workers’
compensation
or
similar
35


-7-


SF
513
(4)
88


pf/rh/mb


7/
8


















S.F.
513


insurance,
or
automobile
medical
payment
insurance.
1


8.


This
section
shall
not
be
construed
to
require
a
2


third-party
payor
to
provide
payment
to
a
practitioner
for
the
3


dispensing
of
a
self-administered
hormonal
contraceptive
to
4


replace
a
self-administered
hormonal
contraceptive
that
has


5


been
dispensed
to
a
covered
person
and
that
has
been
misplaced,


6


stolen,
or
destroyed.
This
section
shall
not
be
construed
to
7


require
a
third-party
payor
to
replace
covered
prescriptions
8


that
are
misplaced,
stolen,
or
destroyed.


9


9.
For
the
purposes
of
this
section:
10


a.


“Self-administered
hormonal
contraceptive”
means
a
11


self-administered
hormonal
contraceptive
that
is
approved
12


by
the
United
Sates
food
and
drug
administration
to
prevent
13


pregnancy.


“Self-administered
hormonal
contraceptive”
includes
14


an
oral
hormonal
contraceptive,
a
hormonal
vaginal
ring,
and
15


a
hormonal
contraceptive
patch,
but
does
not
include
any
drug
16


intended
to
induce
an
abortion
as
defined
in
section
146.1.
17


b.


“Standing
order”
means
a
preauthorized
medication
order
18


with
specific
instructions
from
the
medical
director
of
the


19


department
of
public
health
to
dispense
a
medication
under
20


clearly
defined
circumstances.


21


Sec.
4.
MEDICAID
COVERAGE
——
SELF-ADMINISTERED
HORMONAL
22


CONTRACEPTIVES.
The
department
of
human
services
shall,
23


contractually
and
by
administrative
rules
adopted
pursuant
24


to
chapter
17A,
require
under
Medicaid
fee-for-service
25


and
Medicaid
managed
care
administration,
coverage
for
26


a
self-administered
hormonal
contraceptive
as
prescribed
27


by
a
practitioner
as
defined
in
section
155A.3,
or
as
28


prescribed
by
standing
order
and
dispensed
by
a
pharmacist
29


pursuant
to
section
155A.47,
including
payment
for
up
to
30


an
initial
three-month
supply
of
the
self-administered
31


hormonal
contraceptive
dispensed
at
one
time
and
for
up
to
a
32


twelve-month
supply
of
the
same
self-administered
hormonal
33


contraceptive
subsequently
dispensed
at
one
time.
34


-8-


SF
513
(4)
88


pf/rh/mb


8/
8

































